In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence. Some background Early-stage...
Read MoreCurrent stage-Stage II (Early) Posts on Medivizor
Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?
In a nutshell The authors investigated the impact of removing radiotherapy (RT) from treatment regimens in patients with early-stage unfavorable Hodgkin lymphoma (HL). This study concluded that this treatment regimen is just as effective as the standard of care. Some background Chemotherapy and consolidation RT is the standard of care for...
Read MoreEarly-stage Hodgkin lymphoma and radiation therapy doses
In a nutshell The purpose of this study was to assess the dose of radiation delivered to organs at risk with modern radiotherapy (RT) in patients with early-stage Hodgkin lymphoma (HL). The authors found that 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and 20Gy of RT for early-stage HL was highly effective...
Read MoreDoes first-line treatment with R-CHOP benefit patients with grade 3A follicular lymphoma?
In a nutshell This study aimed to compare the effectiveness of 2 drug regimens for patients with grade 3A follicular lymphoma (FL3A). The authors concluded that R-CHOP has a benefit over RB in the treatment of these patients. Some background Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL).FL usually has good...
Read MoreStanford V chemotherapy and limited filed irradiation for patients with unfavorable risk stage I-II classic Hodgkin lymphoma
In a nutshell This study aimed to investigate the long-term outcomes for patients with stage I-II classic Hodgkin lymphoma and unfavorable risk who were treated with Stanford V combined modality therapy. This study concluded that the long-term outcomes for these patients were favorable and comparable to other standard...
Read MoreManaging patients with limited-stage Hodgkin lymphoma by brentuximab vedotin based therapy
In a nutshell The study evaluated if brentuximab-vedotin (BV; Adcetris) consolidation therapy can reduce the use of radiation therapy (RT) in patients with limited-stage (LS) Hodgkin lymphoma (HL). The authors found that BV consolidation achieved good outcomes in such patients when given after ABVD therapy. Some background HL is a cancer of the...
Read More10 year outcomes of early-stage Hodgkin lymphoma
In a nutshell This study looked at long-term outcomes of patients with early-stage Hodgkin lymphoma according to different treatments. It found that patients who received both radiation and chemotherapy had improved long-term survival compared to either treatment alone. Some background At present, over 90% of patients with classical Hodgkin lymphoma...
Read MoreCan PET scanning help guide treatment for patients with Hodgkin’s lymphoma?
In a nutshell This study evaluated whether PET scanning after chemotherapy might help predict outcomes and guide treatment for patients with early-stage Hodgkin's lymphoma (HL). This study found that PET scanning can help identify high-risk patients after chemotherapy. Some background Chemotherapy combined with radiotherapy is the standard of...
Read MoreLooking for patients with aggressive B-cell NHL to try an experimental combination treatment
In a nutshell This study is investigating how well nivolumab (Opdivo) works with DA-REPOCH chemotherapy for treating aggressive B-cell non-Hodgkin's lymphoma (NHL). The primary outcome to be measured is 2-year survival without disease progression after treatment. This study is being conducted in Columbus, OH, in the United States. The...
Read MoreEvaluating A+AVD chemotherapy for patients with early-stage Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness and safety of a modified chemotherapy regimen for patients with early-stage Hodgkin lymphoma (HL). This study concluded that this regimen was effective but associated with more side effects. Some background The most commonly used frontline chemotherapy regimen for HL is ABVD (doxorubicin,...
Read MorePET scanning for predicting outcomes for early-stage Hodgkin lymphoma
In a nutshell This study assessed the usefulness of PET scanning in determining outcomes for patients with early-stage Hodgkin lymphoma (HL). This study concluded that PET scanning after chemotherapy was strongly associated with patient outcomes in early-stage HL. Some background For patients with HL, the goal of treatment is to improve outcomes...
Read MoreSearching for patients with relapsed or unresponsive follicular lymphoma to trial a new drug
In a nutshell This trial will evaluate the effects of a new treatment parsaclisib (INCB050465) in relapsed or unresponsive follicular lymphoma (FL). Response rate, survival, and side effects will be the main outcomes measured. The details Many patients are cured with treatments for follicular lymphoma (FL). Some, however, lose response to therapy...
Read More